Compare Citius Pharmaceuticals Inc (CTXR) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while SYSCO Corporation trades at $80.93 (market cap $39.62B). The key difference: SYSCO Corporation is far larger — about 2706.3× Citius Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.66% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SYY | |
|---|---|---|
Market Cap | $14.64M | $39.62B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $91.16 |
52-Week Low | $0.53 | $69.30 |
Enterprise Value | $10.86M | $53.10B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Sysco Corporation (SYY) trades at $83.46, down 0.44% on the day, with a bullish technical signal and positive analyst sentiment. The stock shows strong fundamentals with consistent revenue growth reaching $81.37B in 2025 and a net income margin of 2.08%. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. The company maintains solid cash flow generation and recently announced a $0.55 dividend payable in July 2026.
Sysco's outlook remains favorable with 60% analyst buy ratings and a consensus price target of $83.67, slightly above current levels. Key opportunities include sustained revenue growth and operational efficiencies, while risks involve margin pressure and competitive industry dynamics. The stock presents a balanced investment case with moderate upside potential amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
